SCHEMBL6741695

SCHEMBL6741695

Fc1cccc(-c2ccc3c(-c4cccnc4)coc3c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 2/20 0.47
ABL1 P00519 1/20 0.41
BCR P11274 1/20 0.41
HPGDS O60760 1/20 0.41
CYP11B2 P19099 4/20 0.40
CYP11B1 P15538 4/20 0.40
CYP19A1 P11511 1/20 0.40
MCL1 Q07820 1/20 0.40
CYP3A4 P08684 3/20 0.40
CYP17A1 P05093 2/20 0.40
ESR2 Q92731 1/20 0.40
CLK4 Q9HAZ1 2/20 0.39
CLK1 P49759 1/20 0.39
DYRK1A Q13627 1/20 0.39
CDC7 O00311 1/20 0.39
ROCK2 O75116 1/20 0.39
MAP4K4 O95819 1/20 0.39
PIM1 P11309 1/20 0.39
PRKACA P17612 1/20 0.39
CDK2 P24941 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6740187 0.91 TDO2 (0.48) TDO2CYP11B2CYP11B1CYP19A1CYP3A4
SCHEMBL6741783 0.89 CYP19A1 (0.49) CYP11B2CYP11B1CYP19A1CYP3A4CYP17A1
SCHEMBL6740241 0.86 ACVR1 (0.48) CYP11B2CYP11B1CYP19A1CYP3A4CYP17A1
SCHEMBL6740852 0.85 CYP3A4 (0.54) CYP11B2CYP11B1CYP19A1CYP3A4CYP17A1
SCHEMBL6736043 0.84 AXL (0.59) TDO2ABL1BCRCYP11B2CYP11B1
SCHEMBL6736802 0.84 CYP19A1 (0.49) CYP11B2CYP11B1CYP19A1CYP3A4CYP17A1
SCHEMBL6741025 0.83 MIF (0.48) CYP11B2CYP11B1CYP19A1CYP3A4CYP1A2
Bromide SCHEMBL6741296 0.82 MIF (0.47) CYP11B2CYP11B1CYP19A1CYP3A4PIM1
SCHEMBL6744153 0.81 PIN1 (0.56) CYP11B2CYP11B1CYP19A1CYP3A4CYP17A1
SCHEMBL6741171 0.80 CYP2A6 (0.56) CYP11B2CYP11B1CYP19A1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6689798-B2 STEROID ALPHA-HYDROXYLASE AND STEROID LYASE INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-02-10 US claimed
US-6689798-B2 STEROID ALPHA-HYDROXYLASE AND STEROID LYASE INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-02-10 US disclosed
US-20030149079-A1 Novel benzofuran derivatives DAIICHI PHARMACEUTICAL CO., LTD. 2003-08-07 US disclosed
EP-1283208-A1 NOVEL BENZOFURAN DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-02-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149079-A1 Novel benzofuran derivatives CYP17A1, CYP21A2, HSD17B7 TDO2 530/4885ABL1 2715/4885BCR 1396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.